| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10919072 | Radiotherapy and Oncology | 2012 | 5 Pages |
Abstract
S-HIFU is an effective curative option for radiorecurrent PCa with acceptable morbidity for localized radiorecurrent PCa, but should be initiated early following EBRT failure. Use of prognostic risk factors can optimize patient selection.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Sébastien Crouzet, Francois-Joseph Murat, Pascal Pommier, Laura Poissonnier, Gilles Pasticier, Olivier Rouviere, Jean-Yves Chapelon, Muriel Rabilloud, Aurélien Belot, Florence Mège-Lechevallier, Hélène Tonoli-Catez, Xavier Martin, Albert Gelet,